https://theranosticatlas.com/feed-imaging.xml 2026-10-26T06:00:00Z LaRadiopharmacie.fr https://theranosticatlas.com/imaging/#nct=NCT06100367#2026-10-26-58237 2026-10-26T06:00:00Z

11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours

https://theranosticatlas.com/imaging/#nct=NCT06790394#2026-10-26-20598 2026-10-26T06:00:00Z

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

https://theranosticatlas.com/imaging/#nct=NCT07814105#2026-10-26-81608 2026-10-26T06:00:00Z

[11C]Metomidate PET-CT vs Usual Care for People With Primary Aldosteronism: a Proof-of-concept Study

https://theranosticatlas.com/imaging/#2026-10-21-29375 2026-10-21T06:00:00Z

Tracking of trials starts; each update adds new trials, changes of phase or status and published results here.

https://pubmed.ncbi.nlm.nih.gov/42112793/#2026-10-01-39256 2026-10-01T06:00:00Z

In 150 patients, this anti-CD70 tracer detects clear cell carcinoma metastases with 94% sensitivity and a 98% PPV. Versus FDG (99 patients), sensitivity 91% vs 41%; management changes in 59% of patients.

https://pubmed.ncbi.nlm.nih.gov/42025513/#2026-10-01-38053 2026-10-01T06:00:00Z

Reanalysis of the pivotal trial: girentuximab also detects CAIX-expressing non-clear cell carcinomas, mostly papillary. For any malignant tumor, PPV of 98%, sensitivity 82% and specificity 87%.

https://pubmed.ncbi.nlm.nih.gov/42809016/#2026-09-29-86672 2026-09-29T06:00:00Z

In stage IV lung cancer, the two anti-PD-L1 tracers show identical uptake, but uptake does not follow PD-L1 expression on immunohistochemistry. Low uptake might herald shorter survival (small cohort, exploratory).

https://pubmed.ncbi.nlm.nih.gov/42784545/#2026-09-24-82012 2026-09-24T06:00:00Z

In 140 patients with newly diagnosed glioblastoma, adding FET PET to MRI enlarges the radiotherapy target volume in 83% of cases. The change is clinically significant in 76% of patients; the impact on tumor control remains to be shown.

https://pubmed.ncbi.nlm.nih.gov/42722441/#2026-09-10-47279 2026-09-10T06:00:00Z

In 30 patients with a renal mass, this anti-CAIX peptide imaged on the same day identifies clear cell carcinoma with 100% sensitivity and 86% specificity. It finds 20 metastases missed by conventional imaging; uptake follows tissue CAIX expression (r = 0.83).

https://pubmed.ncbi.nlm.nih.gov/42315309/#2026-09-02-75192 2026-09-02T06:00:00Z

In 217 randomized men with a PI-RADS 4 or 5 lesion, robotic biopsy guided by PSMA PET detects cancer in 97% of patients vs 81% for ultrasound-guided biopsy with cognitive MRI fusion. Fewer complications (11% vs 51%), less pain and fewer cores.

https://pubmed.ncbi.nlm.nih.gov/41793320/#2026-09-01-47863 2026-09-01T06:00:00Z

In suspected giant cell arteritis (103 patients), ultrasound remains the best first-line test (sensitivity 82%). FDG PET is 100% specific with few inconclusive results: a second-line test, before temporal artery biopsy.

https://pubmed.ncbi.nlm.nih.gov/42670739/#2026-08-30-22914 2026-08-30T06:00:00Z

In 126 patients with suspected cardiac amyloidosis, this pan-amyloid tracer (AL as well as ATTR forms) is positive in every patient with the disease and negative in all others: 100% sensitivity and specificity, excellent inter-reader agreement (κ 0.94).

https://pubmed.ncbi.nlm.nih.gov/42048392/#2026-08-14-38560 2026-08-14T06:00:00Z

In triple-negative breast cancer (22 patients), FDG and FLT are reproducible; FDG was chosen. Its drop in uptake after a single cycle predicts the final pathological response better than MRI. Small cohort; validation needed.

https://pubmed.ncbi.nlm.nih.gov/42167805/#2026-08-03-4168 2026-08-03T06:00:00Z

In 61 patients with colorectal or ovarian peritoneal carcinomatosis, FAPI PET agrees best with surgical staging (ICC 0.81 vs 0.76 for MRI and 0.54 for FDG). More sensitive but less specific; performance maintained after chemotherapy.

https://pubmed.ncbi.nlm.nih.gov/42307959/#2026-08-01-83509 2026-08-01T06:00:00Z

In 6 European centres (148 patients), PET/CT of the surgical specimen after a low FDG dose allows margins to be corrected during surgery: 95% success vs 83% without intraoperative assessment and 87% with the usual techniques.

https://pubmed.ncbi.nlm.nih.gov/42610817/#2026-08-01-79482 2026-08-01T06:00:00Z

In 48 patients, uptake of the anti-PD-L1 tracer correlates strongly with the immunohistochemistry tumor score (ρ 0.80). It reveals heterogeneity that a single biopsy misses: 5 patients classified as negative had avid lesions. Uptake is higher in lesions responding to immunotherapy.

https://pubmed.ncbi.nlm.nih.gov/42496850/#2026-07-24-48180 2026-07-24T06:00:00Z

In Japan, in 9 men, PSMA-11 labeled with cyclotron-produced gallium-68 (automated module, about 2.8 GBq per synthesis, purity above 99%) is well tolerated, with expected dosimetry and all primary lesions detected.

https://pubmed.ncbi.nlm.nih.gov/42255253/#2026-07-01-31334 2026-07-01T06:00:00Z

In 385 patients randomized at diagnosis, staging with PSMA-1007 PET classifies fewer patients as non-metastatic than sodium fluoride PET (69% vs 77%), but progression-free survival does not differ significantly (HR 0.74, p = 0.19). A favourable trend in high-risk patients; longer follow-up needed.

https://pubmed.ncbi.nlm.nih.gov/41857358/#2026-07-01-68205 2026-07-01T06:00:00Z

In 38 patients, this anti-CAIX tracer is more accurate (94% vs 71%) and more specific (97% vs 62%) than FDG, with comparable sensitivity. Limited value for lymph nodes; uptake collapses under tyrosine kinase inhibitors.

https://pubmed.ncbi.nlm.nih.gov/42128226/#2026-07-01-34723 2026-07-01T06:00:00Z

Pre-specified subgroup of 298 obese patients from the phase 3 trial: flurpiridaz PET meets its primary endpoint and is more sensitive than technetium scintigraphy for two of three readers. No loss of performance in obese patients.

https://pubmed.ncbi.nlm.nih.gov/42247617/#2026-07-01-98055 2026-07-01T06:00:00Z

First-in-human use (4 volunteers) of this fluorinated norepinephrine transporter tracer, an alternative to MIBG: simple synthesis, no serious adverse event, effective dose of 22 µSv/MBq and good visualisation of the myocardium at late time points.

https://pubmed.ncbi.nlm.nih.gov/42378054/#2026-06-30-98502 2026-06-30T06:00:00Z

In 50 patients, this anti-BCMA tracer is more sensitive (97% vs 85%) and more specific (71% vs 60%) than FDG. The measured tumor burden tracks myeloma markers and changed treatment decisions.

https://pubmed.ncbi.nlm.nih.gov/42337037/#2026-06-24-32481 2026-06-24T06:00:00Z

Multicentre study in 24 patients with raised calcitonin after surgery: FDOPA PET detects 1.5 times more metastatic lymph nodes than conventional imaging and changes management in 58% of cases. Reading is demanding, with a learning curve.

https://pubmed.ncbi.nlm.nih.gov/42269655/#2026-06-10-69844 2026-06-10T06:00:00Z

In 660 men at high clinical risk but with a non-suspicious or equivocal MRI (PI-RADS 2-3), first-line PSMA PET is non-inferior to systematic biopsy for detecting significant cancer (12% vs 16%) and avoids biopsy in 49% of patients. Comparable biopsy safety.

https://pubmed.ncbi.nlm.nih.gov/42234002/#2026-06-03-62421 2026-06-03T06:00:00Z

In 41 untreated patients, PentixaFor detects far more disease sites than FDG (lymph nodes 97% vs 40%, stomach 72% vs 40%). It changes the stage in 29% of patients and management in 56%.

https://pubmed.ncbi.nlm.nih.gov/41904043/#2026-06-01-12672 2026-06-01T06:00:00Z

In 50 patients with early biochemical recurrence after prostatectomy (median PSA 0.43), copper-64 bisPSMA imaged at 24 h detects 2.6 times more lesions than gallium PSMA-11 and is positive in 78% of patients vs 36%. Management changes in 44% of patients.

https://pubmed.ncbi.nlm.nih.gov/41784782/#2026-06-01-96517 2026-06-01T06:00:00Z

In 130 men with suspected cancer after at least one negative biopsy, the PSMA PET PRIMARY score is more accurate than MRI PI-RADS (92% vs 83%). The authors derive a predictive nomogram before repeat biopsy (AUC 0.90).

https://pubmed.ncbi.nlm.nih.gov/41762267/#2026-06-01-12641 2026-06-01T06:00:00Z

In 50 patients with biochemical recurrence at low PSA (0.2 to 2 ng/mL) after robotic prostatectomy, DCFPyL is positive in 44% of cases vs 24% for fluciclovine, with a clear advantage for pelvic lymph nodes (22% vs 8%).

https://pubmed.ncbi.nlm.nih.gov/42377125/#2026-06-01-72340 2026-06-01T06:00:00Z

In 134 patients with recurrence after prostatectomy, randomized between the two tracers, PET changes the radiotherapy decision in 29% (fluciclovine) and 42% (PSMA) of cases, with no significant difference between tracers. Radiation fields change more often with fluciclovine.

https://pubmed.ncbi.nlm.nih.gov/41887731/#2026-06-01-98745 2026-06-01T06:00:00Z

First-in-human injection (10 patients) of this technetium-labeled SSTR2 antagonist: well tolerated, effective dose of 3.3 mSv. On SPECT, it detects as many or more lesions than gallium SSTR PET, with at least twice the contrast.

https://pubmed.ncbi.nlm.nih.gov/41872337/#2026-06-01-9106 2026-06-01T06:00:00Z

Radiolabeled antibody targeting misfolded SOD1 in ALS, tested in 7 volunteers and 1 patient: no serious adverse event, liver as the limiting organ, effective dose of 0.2 to 0.3 mSv/MBq. Higher spinal cord uptake in the patient, to be confirmed.

https://pubmed.ncbi.nlm.nih.gov/41989806/#2026-06-01-40135 2026-06-01T06:00:00Z

In 200 patients with metastatic breast cancer, an FDG PET without progression after 2 weeks of treatment has a 95% NPV for progression on CT at 8 weeks. Median progression-free survival of 19.4 vs 4.1 months according to the early PET.